RSS Feeds | Pharmaceutical Benefits Scheme Change For Crohns Disease
August 19, 2007 08:00:00A change to the Pharmaceutical Benefits Scheme (PBS) from 1 October 2007 will provide subsidised access to adults and children of Remicade® (infliximab) for the treatment of Crohns disease.Crohns disease is an inflammatory disorder of the gastrointestinal tract. It can have a profound impact on professional, family and social life. Those with active Crohns disease experience chronic abdominal pain, diarrhoea and bowel movements containing blood. [click link for full article] - [Read more] |
| Having A Pet Pig May Offer Some Benefits
August 15, 2007 10:00:00Contact with farm environments in infancy might decrease the risk of juvenile Crohns disease and ulcerative colitis. Thats according to a study conducted in Germany entitled, "Contact With Farm Animals in Early Life and Juvenile Inflammatory Bowel Disease: A Case-Control Study." Parents of children (ages 6 to 18) from 13 hospitals received a questionnaire regarding consumption of raw milk, contact with farm animals or pets, age of contact, and presence of respiratory allergies. [click link for full article] - [Read more] |
| Joint FDA Advisory Committee Recommends Approval Of TYSABRI® For The Treatment Of Moderate To Sever
August 6, 2007 07:00:00Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced today that the Gastrointestinal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 12 in favor to 3 opposed, with 2 abstaining, to recommend approval of TYSABRI® (natalizumab) as a treatment for moderate-to-severe Crohns disease in patients who have failed or cannot tolerate available therapies. [click link for full article] - [Read more] |
| Elan And Biogen Idec Preparing To Appeal Ruling On European Application For Natalizumab For The Trea
July 23, 2007 07:00:00Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced today that they have been informed by the European Medicines Agency (EMEA) that the Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion on the marketing application for the use of natalizumab in patients with Crohns disease. In accordance with European regulations, Elan and Biogen Idec plan to apply for a re-examination of the negative opinion through the appeal procedure. [click link for full article] - [Read more] |
| Certolizumab Pego Found To Be Effective New Therapy For Patients With Crohns Disease
July 21, 2007 18:00:00Mayo Clinic researchers have found that Certolizumab pegol is an effective treatment for adults with Crohns disease, according to two new studies. These findings were published in todays issue of the New England Journal of Medicine. Certolizumab pegol blocks tumor necrosis factor, an important cause of inflammation in Crohns disease.Crohns disease is an inflammatory disorder of the gastrointestinal tract that affects an estimated 500,000 people in the United States. [click link for full article] - [Read more] |
| Gene Identified For Crohns Disease In Children
July 19, 2007 07:00:00Pediatrics researchers have identified a gene variant that raises a childs risk of Crohns disease, a chronic and painful condition attributed to inflammation of the gastrointestinal tract. The research reinforces previous results by German researchers, who found the same gene variant associated with the adult form of Crohns disease. [click link for full article] - [Read more] |
| First-time Link Between Food Intolerance And Illness
July 12, 2007 07:00:00Researchers from University College London have found compelling evidence for the first time to link food intolerances and serious illness.A six-month programme has shown potential links with foodstuffs and Crohns Disease, and ulcerative colitis.The discovery could prompt an entire rethink in the medical profession across a range of conditions, from irritable bowel syndrome to migraine. [click link for full article] - [Read more] |
| Kids With Crohns Disease Find Comfort, Leading-edge Treatment At Pediatric Infusion Center
July 6, 2007 07:00:00Seventeen-year-old Eliot Drieband explains what its like to have Crohns disease a type of inflammatory bowel disease in the same matter-of-fact way she describes preparing for an advanced placement exam, working on the school newspaper, starting an organ donor awareness club for teens and being a peer counselor for other kids facing chronic, life-altering illnesses. [click link for full article] - [Read more] |
| Abbott Launches Humira (Adalimumab) For Crohns Disease
June 14, 2007 08:00:00Abbott launches HUMIRA® (adalimumab) as a treatment for severe, active Crohns disease. Adalimumab is the first fully-human tumour necrosis factor antagonist (anti-TNF) to receive a licence for Crohns disease, a chronic inflammatory disease of the gastrointestinal tract that impairs the lives of up to 60,000 people in the UK1 and causes 70-80% of patients to require major surgery within their lifetime. [click link for full article] - [Read more] |
| Remicade® Receives EU Approval As First And Only Biologic Treatment For Paediatric Crohns Disease
June 14, 2007 08:00:00The European Commission (EC) has approved a new indication for Remicade® (infliximab) allowing for the treatment of severe, active Crohns disease (CD) in paediatric patients aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy, or who are intolerant to, or have contraindications for, such therapies. Infliximab has been studied only in combination with conventional immunosuppressive therapy. [click link for full article] - [Read more] |
| Protein C Signaling Impacts Inflammatory Bowel Disease
June 13, 2007 03:00:00Inflammatory bowel disease, which includes Crohns disease and ulcerative colitis, involves both immune and nonimmune cells. Previous studies have established that the vasculature of the gut mucosa is an important nonimmune component of intestinal inflammation and that the protein C (PC) signaling pathway is an important checkpoint in the inflammatory process. [click link for full article] - [Read more] |
| First-Step Test For Patients With Crohns Disease Should Be PET/CT
June 9, 2007 01:00:00The molecular imaging power of PET/CT is invaluable in noninvasively monitoring Crohns disease - a chronic inflammatory disease of the gastrointestinal tract that mainly affects young people, according to a study released by Belgian scientists at the 54th Annual Meeting of SNM, the worlds largest society for molecular imaging and nuclear medicine professionals. [click link for full article] - [Read more] |
| Abbotts HUMIRA® (Adalimumab) Approved In The European Union For The Treatment Of Crohns Disease
June 8, 2007 08:00:00Abbott announced today that it has received marketing authorization from the European Commission for the use of HUMIRA® (adalimumab) as a treatment for severe Crohns disease. HUMIRA is the first self-administered biologic for the treatment of Crohns disease and offers an effective and convenient treatment option that can help enable patients to maintain control of their disease. [click link for full article] - [Read more] |
| Remicade(R) Receives EU Approval As First And Only Biologic Treatment For Pediatric Crohns Disease
June 8, 2007 07:00:00Centocor, Inc. and Schering-Plough Corporation (NYSE: SGP) today announced that the European Commission has approved a new indication for REMICADE(R) (infliximab) allowing for the treatment of severe, active Crohns disease (CD) in pediatric patients aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy, or who are intolerant to, or have contraindications for, such therapies. [click link for full article] - [Read more] |
| Large Genome Study Finds Genes Behind Common Diseases
June 7, 2007 07:00:00In the largest ever study published to date, a consortium of UK scientists has discovered over 20 genes and regions of the human genome that contribute to diseases such as diabetes, rheumatoid arthritis and coronary heart disease.The Wellcome Trust Control Consortiums 9 million pound study is a collaboration of 200 UK scientists from 50 teams at dozens of UK institutions. [click link for full article] - [Read more] |
| In Crohns Disease CEACAM6 Helps E. Coli Stick To Intestinal Lining
May 30, 2007 20:00:00In Crohns disease, the lining of the small intestine is abnormally colonized by E. coli organisms that are able to adhere to and invade intestinal epithelial cells. In a study appearing online in advance of publication in the June print issue of the Journal of Clinical Investigation, Arlette Darfeuille-Michaud and colleagues from Universite dAuvergne, France, show that the adherent-invasive E. [click link for full article] - [Read more] |
| ECP May Be Effective In Treating Crohns Disease
May 30, 2007 08:00:00Results from an international multi-center Phase II clinical trial suggest that extracorporeal photopheresis (ECP) may be effective in treating patients with clinically active (OR symptomatic) Crohns disease who cannot tolerate or are refractory to immunosuppressants and/or anti-TNF agents. [click link for full article] - [Read more] |
| New Analysis Of Data Shows Treatment With Abbotts HUMIRA® Significantly Reduced Disease-Related Ho
May 24, 2007 19:00:00Abbott today announced results from a post-hoc analysis of a pivotal study presented at the Digestive Disease Week annual meeting in Washington, D.C. showing patients with moderate to severely active Crohns disease treated with HUMIRA® (adalimumab) maintenance therapy were almost 60 percent less likely than patients on placebo to be hospitalised due to their disease at one year (5.9 percent versus 13.9 percent; p [click link for full article] - [Read more] |
| Capsule Endoscopy Is Effective In Diagnosing Childhood GI Problems
May 24, 2007 07:00:00Researchers at Jefferson Medical College have shown that capsule endoscopy is effective in diagnosing gastrointestinal bleeding and small bowel Crohns disease in children. The technology has been used successfully at Thomas Jefferson University Hospital for more than five years to diagnose unexplained abdominal bleeding in adults. [click link for full article] - [Read more] |
|
|
